6 Signs You're Going to Break at IND: And Don't Know It Yet

Life sciences has changed dramatically over the last decade. Faster development cycles, software and AI embedded in R&D, more regulatory frameworks running in parallel.

Compliance hasn't kept pace.

And nowhere does that gap become more visible, and more costly, at IND.

Most growth-stage biotech companies don't fail at IND because they were unprepared. They fail because they thought they were ready. A clean GLP audit creates confidence. It signals control. It suggests your quality system is working. And after months of running lean and making it work, that signal feels like validation.

But IND doesn't test whether your system worked in preclinical. It tests whether your system can handle what comes next.

Filing triggers 21 CFR Part 312 requirements. ICH E6 GCP obligations layer in. CDMO oversight becomes a real accountability structure. CRO execution introduces new coordination demands across sites and functions. And often, a new VP of Quality or Head of RA steps in and inherits a system built for a much simpler operating model.

At that moment, a gap appears.

The gap between what your system can support and what clinical-stage compliance demands is filled by one thing: human effort. Late nights, manual reconciliation, fragile workarounds.

We call this the Heroics Gap: the extra manual effort required to stretch a research-focused system into clinical-stage compliance. Heroics don't eliminate risk. They postpone when that risk becomes visible, and compound the cost when it does.

Here are six signs your system is running on heroics, not infrastructure.

Sign 1: Your Audit Prep Is Measured in Weeks, Not Days

If preparing for a regulatory touchpoint requires 80 to 160 hours of QA time pulling documents, reconciling records, and chasing evidence across systems, your readiness is episodic.

You're reconstructing compliance, not maintaining it.

Today, most growth-stage biotech teams manage this through one of two approaches: manual ops (spreadsheets, shared drives, email) or fragmented reactive systems built for passing audits, not maintaining continuous readiness. Both approaches work in preclinical. At IND, the frequency of regulatory touchpoints increases, the documentation demands multiply, and the window to respond to any request shrinks.

Audit readiness shouldn't be an event. It should be a state. If yours isn't, that's your first sign.

Related: Audit-Ready vs Scale-Ready: Why Passing Is Not Proof →

Sign 2: Your CDMO Oversight Lives Outside Your Quality System

If vendor qualification records, manufacturing data, and CMC documentation live in spreadsheets, shared drives, or email threads, you don't have CDMO oversight. You have partial visibility, on a good day.

Partial visibility can feel sufficient when things are running smoothly. The real competition at this stage isn't a competing QMS vendor. It's the combination of manual ops, headcount, and fragmented tools that let you keep going without a unified system of record. That combination works until one deviation, one unannounced audit, or one key personnel change exposes how thin the coverage actually is.

When that happens, you're looking at a multi-week remediation cycle triggered at exactly the moment you can least afford it: during IND preparation, during CMC review, or during a diligence process.

CDMO oversight isn't a best practice. At IND, it's a structural requirement. If it's not embedded in your quality system, it's a liability you're carrying without knowing it.

Related: Your Compliance Model: Effective Now, Vulnerable Later →

Sign 3: Your SOPs Get Updated Before Inspections, Not Continuously

If your SOPs are reviewed and revised in the weeks leading up to a regulatory event, that's not a quality system. That's a documentation sprint.

Regulators notice. Investors notice. Your own team notices, because they're the ones pulled away from execution to participate in the sprint.

The issue isn't that your SOPs are wrong. It's that periodic, milestone-driven updates don't reflect how your organization actually operates day to day. In clinical, the gap between documented process and actual practice is exactly what inspectors are trained to find.

Continuous document control isn't a resource question. It's an architecture question. If your system doesn't make continuous updates easier than periodic sprints, the sprint will always win, until it can't.

Sign 4: CRO Change Control Runs Through Email

Clinical execution oversight isn't a best practice. It's a requirement.

Protocol changes, investigator updates, site qualifications, protocol deviations: these need to exist in a structured, traceable system. When they're managed through email threads with no connection to your quality system, every update creates undocumented risk.

In the moment, it feels manageable. Email is fast. It's familiar. Everyone's already in it. But email is change communication, not change control. Those are not the same thing.

When you need to trace a decision during an audit, during a deviation investigation, or during a regulatory inquiry, the email chain becomes unexplainable. You have a record that something happened. You don't have a record that satisfies the standard for how decisions are made and approved in a clinical-stage organization.

Related: Continuous Readiness Is Becoming the New Operating Standard →

Sign 5: Your Risk Register Isn't Connected to Your Clinical Reality

If your risk register is a standalone document, updated manually before major milestones, it isn't risk management. It's risk documentation.

The distinction matters because regulators aren't looking only for evidence that you identified risks. They're looking for evidence that your risk management informs your decisions. There needs to be a traceable connection between what you anticipated and how you responded.

When a clinical deviation needs to be connected to a prior risk assessment and no system-level link exists, that gap doesn't stay hidden. It surfaces under exactly the conditions where you need the most credibility: inspection, deviation review, escalation.

A risk register that lives in a document lives outside your quality system. At IND, that's not a minor gap. It's a structural vulnerability.

Sign 6: Too Much of Your System Lives in One Person's Head

If a new VP of Quality or Head of RA needs weeks to understand how your quality processes actually work, your system isn't operationalized. It's person-dependent.

Person-dependent systems feel stable when the person is there. They can look perfectly functional from the outside. But they create fragility at the exact moments you need reliability: IND submission, first regulatory interactions, Series B diligence.

Leadership transitions at clinical-stage companies happen regularly. If your quality system doesn't transfer cleanly, if onboarding a new leader requires tribal knowledge, undocumented conventions, and weeks of shadow work, the system doesn't scale.

A system that doesn't scale beyond a single individual isn't infrastructure. It's a single point of failure.

The Pattern Behind All Six Signs

Every one of these signs reflects a quality system still built for research, not clinical complexity.

None of these gaps are visible in preclinical. The operating model in preclinical is simpler. Regulatory exposure is narrower. Coordination demands are lower. A system built for that environment can look perfectly functional, until the environment changes.

IND is where they compound, simultaneously.

The Heroics Gap is what keeps these systems running longer than they should. Smart, capable people work harder to compensate for structural gaps. The system doesn't fail. It just requires more human effort to keep functioning. And that effort hides the risk until the risk becomes unavoidable.

What It Actually Costs

These gaps don't show up first as inspection findings. They show up as operational problems:

A 30 to 60 day IND delay caused by documentation gaps identified late in the review process. A CDMO remediation cycle triggered mid-IND preparation, pulling key resources away from filing work. A diligence issue that slows or reshapes a Series B because an investor's quality review surfaced what your internal review missed.

IND isn't just a regulatory milestone. It's the point where operational gaps become business risks, and the cost of fixing them increases significantly.

The Reality Most Teams Miss

Phase I doesn't create these problems.

IND removes your ability to hide them.

Once you're in it, fixes take longer, cost more, and happen under higher visibility. What could have been addressed structurally, with time and optionality, becomes reactive work under pressure.

The window to close these gaps on your terms is the 6 to 9 months before IND. Not during. Not after. Before.

Before IND Becomes the Stress Test

If you're within 6 to 9 months of IND, this isn't theoretical. The signs are already present, or they're not. But the only way to know is to look clearly, before the filing date forces the answer.

The IND Stress Test is a short diagnostic built for exactly this moment. It maps where your quality system is structurally ready for clinical-stage demands, and where it isn't, before IND exposes the gaps under the worst possible conditions.

It takes less time than one documentation sprint. And it gives you the one thing you can't recover once IND starts: lead time.

Qualio is the Agentic Compliance Platform for Life Sciences, built so growth-stage biotech companies can run compliance in parallel with product development, without the heroics. Learn more about how Qualio supports biotech compliance →